The financial investors AFINUM Achte Beteiligungsgesellschaft mbH & Co. KG and SHS V Medtech Investments GmbH & Co. KG have acquired evitria AG, a leading provider of custom antibodies.

evitria AG with its domicile in Schlieren, Switzerland, services a broad spectrum of pharmaceutical and biotech companies as well as research institutions worldwide with antibody-based molecules. Through the use of a unique production process evitria AG is able to minimize throughput times and to guarantee high concentration and quality levels.

The demand for antibodies tailored to specific research purposes is expected to grow significantly in the coming years. Together with its new owners, evitria AG therefore plans to exploit additional customer groups and to further expand internationally.

A team of CMS Zurich lead by partner Stephan Werlen advised sell side on all legal matters of the transaction.

CMS Switzerland
Dr Stephan Werlen, Partner, Corporate / M&A
Pascal Stocker, Associate, Corporate / M&A
Andrea Zindel, Associate, Corporate / M&A
Dr Simone Brauchbar Birkhäuser, Counsel, IP / IT